Innoviva Price to Sales Ratio 2010-2023 | INVA

Historical PS ratio values for Innoviva (INVA) over the last 10 years. The current P/S ratio for Innoviva as of April 19, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Innoviva P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-04-19 14.95 3.88
2023-12-31 16.04 $3.86 4.16
2023-09-30 12.99 $3.56 3.65
2023-06-30 12.73 $3.48 3.66
2023-03-31 11.25 $3.37 3.33
2022-12-31 13.25 $3.48 3.80
2022-09-30 11.61 $3.94 2.95
2022-06-30 14.76 $4.43 3.33
2022-03-31 19.35 $4.30 4.50
2021-12-31 17.25 $4.09 4.21
2021-09-30 16.71 $3.75 4.46
2021-06-30 13.41 $3.33 4.02
2021-03-31 11.95 $3.03 3.95
2020-12-31 12.39 $2.97 4.18
2020-09-30 10.45 $2.84 3.68
2020-06-30 13.98 $2.64 5.30
2020-03-31 11.76 $2.51 4.69
2019-12-31 14.16 $2.30 6.15
2019-09-30 10.54 $2.34 4.51
2019-06-30 14.56 $2.30 6.33
2019-03-31 14.03 $2.33 6.03
2018-12-31 17.45 $2.30 7.58
2018-09-30 15.24 $2.18 7.00
2018-06-30 13.80 $2.04 6.77
2018-03-31 16.67 $1.93 8.62
2017-12-31 14.19 $1.81 7.85
2017-09-30 14.12 $1.58 8.92
2017-06-30 12.80 $1.45 8.83
2017-03-31 13.83 $1.18 11.75
2016-12-31 10.70 $1.10 9.71
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.945B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55